Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief
Background: Allocation of the new (expensive) drugs for difficult refractory diseases and financial protection of the patients is an important challenge in the national health systems worldwide especially in developing countries. Trastuzumab (Herceptin) as one of the effective but expensive drugs...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2014-04-01
|
Series: | Basic & Clinical Cancer Research |
Subjects: | |
Online Access: | https://bccr.tums.ac.ir/index.php/bccrj/article/view/133 |
id |
doaj-5607b904191042298763b50251457287 |
---|---|
record_format |
Article |
spelling |
doaj-5607b904191042298763b502514572872021-04-04T07:07:38ZengTehran University of Medical SciencesBasic & Clinical Cancer Research2228-65272228-54662014-04-0162Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy BriefMohammad Reza Rouhollahi0Samad Mohammd Nejad1Iraj Harirchi2Behrouz Zarei3Gelavizh Keshtmand4Sanambar Sadighi5Saeid Amanpour6Afshin Abdirad7Parviz Kokhaei8Mehdi Aghili9Farnaz Amoozegar-Hashemi10Mojtaba Vandrajabpour11Kazem Zendehdel12Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Model Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCorporate Entrepreneurship Department, University of Tehran, Tehran, Iran.Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Model Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranImmunology Department of Medical Faculty, Semnan University of Medical Sciences, Semnan, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, IranCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran Background: Allocation of the new (expensive) drugs for difficult refractory diseases and financial protection of the patients is an important challenge in the national health systems worldwide especially in developing countries. Trastuzumab (Herceptin) as one of the effective but expensive drugs, put major financial burden for the Iranian patients and government. So the Ministry of Health and Medical Education (MOHME), decided to implement a national program for appropriate management of breast cancer and regulation of Trastuzumab in I.R of Iran (NPMBCT). In this policy brief we evaluated this issue and provided necessary recommendations. Method: We designed a conceptual model consisting of the goals, main and supporting processes for management of Trastuzumab in the national program. Five macro-processes selected as the main concerns. Then an expert panel including different scientific disciplines discussed the different aspects of the issue and provided the necessary recommendations. We determined the link between the suggested recommendations and the objectives of the program. Results: Based on the five selected main processes, the experts provided 10 recommendations including: 1) balance in the resource allocation, 2) appropriate modeling for the subsides allocation, 3) avoiding “poor subsidize the rich†phenomenon, 4) development and updating the clinical guidelines, 5) cost-effectiveness analysis on accepted guideline, 6) Quality improvement of diagnostic tests, 7) standardization of the laboratory kits, 8) brand management and lowering the drug cost, 9) improving the patient registry system by ICT infra-structure, 10) development of expert systems to empower the diagnostic laboratories. Conclusion: Given these recommendations, the NPMBCT program will be a successful model for the appropriate management of the expensive drugs and treatment of breast cancer in I.R. of Iran and other developing countries. https://bccr.tums.ac.ir/index.php/bccrj/article/view/133TrastuzumabBreast CancerIranmanagementNew High-Cost Cancer Drugs (NHCCD) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mohammad Reza Rouhollahi Samad Mohammd Nejad Iraj Harirchi Behrouz Zarei Gelavizh Keshtmand Sanambar Sadighi Saeid Amanpour Afshin Abdirad Parviz Kokhaei Mehdi Aghili Farnaz Amoozegar-Hashemi Mojtaba Vandrajabpour Kazem Zendehdel |
spellingShingle |
Mohammad Reza Rouhollahi Samad Mohammd Nejad Iraj Harirchi Behrouz Zarei Gelavizh Keshtmand Sanambar Sadighi Saeid Amanpour Afshin Abdirad Parviz Kokhaei Mehdi Aghili Farnaz Amoozegar-Hashemi Mojtaba Vandrajabpour Kazem Zendehdel Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief Basic & Clinical Cancer Research Trastuzumab Breast Cancer Iran management New High-Cost Cancer Drugs (NHCCD) |
author_facet |
Mohammad Reza Rouhollahi Samad Mohammd Nejad Iraj Harirchi Behrouz Zarei Gelavizh Keshtmand Sanambar Sadighi Saeid Amanpour Afshin Abdirad Parviz Kokhaei Mehdi Aghili Farnaz Amoozegar-Hashemi Mojtaba Vandrajabpour Kazem Zendehdel |
author_sort |
Mohammad Reza Rouhollahi |
title |
Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief |
title_short |
Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief |
title_full |
Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief |
title_fullStr |
Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief |
title_full_unstemmed |
Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief |
title_sort |
recommendations for management of the trastuzumab (herceptin) among iranian breast cancer patients, a policy brief |
publisher |
Tehran University of Medical Sciences |
series |
Basic & Clinical Cancer Research |
issn |
2228-6527 2228-5466 |
publishDate |
2014-04-01 |
description |
Background: Allocation of the new (expensive) drugs for difficult refractory diseases and financial protection of the patients is an important challenge in the national health systems worldwide especially in developing countries. Trastuzumab (Herceptin) as one of the effective but expensive drugs, put major financial burden for the Iranian patients and government. So the Ministry of Health and Medical Education (MOHME), decided to implement a national program for appropriate management of breast cancer and regulation of Trastuzumab in I.R of Iran (NPMBCT). In this policy brief we evaluated this issue and provided necessary recommendations.
Method: We designed a conceptual model consisting of the goals, main and supporting processes for management of Trastuzumab in the national program. Five macro-processes selected as the main concerns. Then an expert panel including different scientific disciplines discussed the different aspects of the issue and provided the necessary recommendations. We determined the link between the suggested recommendations and the objectives of the program.
Results: Based on the five selected main processes, the experts provided 10 recommendations including: 1) balance in the resource allocation, 2) appropriate modeling for the subsides allocation, 3) avoiding “poor subsidize the rich†phenomenon, 4) development and updating the clinical guidelines, 5) cost-effectiveness analysis on accepted guideline, 6) Quality improvement of diagnostic tests, 7) standardization of the laboratory kits, 8) brand management and lowering the drug cost, 9) improving the patient registry system by ICT infra-structure, 10) development of expert systems to empower the diagnostic laboratories.
Conclusion: Given these recommendations, the NPMBCT program will be a successful model for the appropriate management of the expensive drugs and treatment of breast cancer in I.R. of Iran and other developing countries.
|
topic |
Trastuzumab Breast Cancer Iran management New High-Cost Cancer Drugs (NHCCD) |
url |
https://bccr.tums.ac.ir/index.php/bccrj/article/view/133 |
work_keys_str_mv |
AT mohammadrezarouhollahi recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT samadmohammdnejad recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT irajharirchi recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT behrouzzarei recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT gelavizhkeshtmand recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT sanambarsadighi recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT saeidamanpour recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT afshinabdirad recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT parvizkokhaei recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT mehdiaghili recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT farnazamoozegarhashemi recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT mojtabavandrajabpour recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief AT kazemzendehdel recommendationsformanagementofthetrastuzumabherceptinamongiranianbreastcancerpatientsapolicybrief |
_version_ |
1721543198688411648 |